Clinical Trials · NCT00076440
Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Voyager Pharmaceutical Corporation
- Enrollment
- 90
- Start date
- Dec 2003
- Locations
- 13 sites, United States
- Primary endpoint
- Study in Alzheimer Disease